Study validates shorter treatment for major world infection, tuberculosis
May 19, 2021
Contact: Will Sansom, (210) 567-2579, sansom@uthscsa.edu SAN ANTONIO (May 19, 2021) — Four months of multi-drug therapy that included rifapentine and moxifloxacin treated active tuberculosis (TB) as effectively as the standard six-month regimen in a multinational study, cutting treatment time by a third. Coauthors including Marc Weiner, MD, of The University of Texas Health Science […]
